EXtended Therapy in Hepatitis C Genotype 3 Infected Patients

PHASE3TerminatedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

February 28, 2010

Primary Completion Date

June 30, 2011

Study Completion Date

June 30, 2011

Conditions
Chronic Hepatitis C
Interventions
DRUG

Peginterferon alfa-2b (Pegetron) plus ribavirin (Rebetol)

Dosage Form: Pegetron - powder for solution; Rebetol - capsules Strength: Pegetron Redipen - 120 mcg per pen; Rebetol - 200 mg Route of Administration: Pegetron - subcutaneous; Rebetol - oral

Trial Locations (12)

T2N 4Z6

Calgary Heart Centre, Calgary

Hys Med Centre, Edmonton

V5Z 1H2

Liver and Intestinal Research Centre, Vancouver

V6A 4B6

Dr. John D Farley Medical Office, Vancouver

V6Z 2K5

Pacific Gastroenterology Assoc, Vancouver

K7L 5G2

Hotel Dieu Hospital, Kingston

N6A 5A5

London Health Sciences Centre, London

L5B 2V2

Dr. Dalia El-Ashry clinic, Mississauga

L5M2V8

Credit Valley Med Arts Centre, Mississauga

M5G 2C4

Toronto General Hospital - Dr. M. Sherman, Toronto

M5T 2S8

Toronto Western Hospital - Liver Clinic, Toronto

H3T 1E2

SMBD Jewish Gen Hosp, Montreal

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Schering-Plough

INDUSTRY

lead

University Health Network, Toronto

OTHER

NCT01095445 - EXtended Therapy in Hepatitis C Genotype 3 Infected Patients | Biotech Hunter | Biotech Hunter